We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Self-Fixating Mesh Platform Helps Repair Hernias

By HospiMedica International staff writers
Posted on 11 Jun 2014
A novel surgical mesh simplifies hernia repair and reduces the complications associated with penetrative mesh fixation using tacks or sutures.

The LifeMesh self-fixating hernia mesh (currently under development), provides strong, atraumatic fixation for the reinforcement of tissue during surgical repair of abdominal wall defects in both inguinal and ventral hernias, and can be placed using either a laparoscopic or open approach. The embedded adhesive, activated by tissue contact, was developed using a biomaterial production process that could also transform nearly any commercial mesh into a self-fixating mesh, thus facilitating greater clinical impact across a range of hernia types.

Image: The LifeMesh self-fixating hernia mesh (Photo courtesy of LifeBond).
Image: The LifeMesh self-fixating hernia mesh (Photo courtesy of LifeBond).

The proprietary adhesive platform works through rapid and biocompatible in situ cross-linking of structural proteins that mimics the biochemical cross-linking cascade of late stage blood coagulation. As the proteins cross-link, they undergo a process of gelation to form an adhesive hydrogel matrix. The result is a network similar to the fibrin network, but with an adhesive strength even greater than that of blood-derived fibrin sealants. The LifeMesh self-fixating hernia mesh is a product of LifeBond (Caesarea, Israel), and follows the company’s flagship product, LifeSeal surgical sealant.

“The successful expansion into a second, nondependent product platform is a great achievement for our company,” said Gideon Sturlesi, CEO of LifeBond. “Following clinical deployment of our first product, LifeSeal Surgical Sealant, LifeBond is now poised to rapidly realize additional products in our next-generation surgical toolbox pipeline.”

“LifeBond is at the forefront of a revolution to utilize biomaterial devices to integrate mechanical support with the body's natural tissue repair process,” said Orahn Preiss-Bloom, MSc, co-founder and COO of LifeBond. “We are excited that we have been able to translate our innovative technology into devices with great potential for patient benefit and look forward to continuing to grow our intellectual property portfolio.”

Related Links:

LifeBond



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Autoclavable Camera System
Precision AC

Latest Surgical Techniques News

Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing

Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery

Robotic Nerve ‘Cuffs’ Could Treat Various Neurological Conditions